NCT03174184View on ClinicalTrials.gov

Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

Rifampin

Oral administration of rifampin at a dosage of 20 mg/kg daily

DRUG

MEROPENEM 2 grams TID

Intravenous administration at a dosage of 2 grams thrice daily

DRUG

MEROPENEM 1 gram TID

Intravenous administration at a dosage of 1 gram thrice daily

DRUG

MEROPENEM 3 grams QD

Intravenous administration at a dosage of 3 grams once daily

DRUG

Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet

Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily

DRUG

Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet

Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily

Trial Locations (1)

7505

Task Applied Science and Stellenbosch University, Stellenbosch

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT03174184 - Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB | Biotech Hunter | Biotech Hunter